Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of sublingual depigmented polymerized Olea europaea allergen extract in seasonal allergic rhinoconjunctivitis
2006-001130-41Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Apr 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Olea europaea pollen allergen extract in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) (2 arms), sponsored by LETI Pharma. Primary endpoint: Total symptom score. Started Apr 2007; status: completed.
02
Drugs
Olea europaea pollen allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2006-001130-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001130-41.